Edgewise Therapeutics (EWTX) Liabilities and Shareholders Equity (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $518.5 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 14.11% year-over-year to $518.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 billion (up 14.3% YoY), and the FY2025 full-year result was $552.6 million, up 13.51% from the prior year.
• Liabilities and Shareholders Equity slipped to $518.5 million in Q1 2026, from $552.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $613.3 million in Q2 2025 to a low of $257.4 million in Q2 2022.
• A 5-year average of $435.8 million and a median of $454.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 64.21% in 2024 and declined 17.95% in 2025, its largest moves.
• Tracing EWTX's Liabilities and Shareholders Equity over 5 years: stood at $367.1 million in 2022, then declined by 7.37% to $340.0 million in 2023, then soared by 43.17% to $486.8 million in 2024, then gained by 13.51% to $552.6 million in 2025, then decreased by 6.17% to $518.5 million in 2026.
• Business Quant data shows EWTX's Liabilities and Shareholders Equity at $518.5 million in Q1 2026, $552.6 million in Q4 2025, and $583.5 million in Q3 2025.